Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

45.4K
Overview
45.4K
Cross-reactivity00:42

Cross-reactivity

31.6K
Overview
31.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structural and immunogenic characterisation of ChAdOx1 Chik-derived Chikungunya VLPs supports a mechanistic rationale for vaccine-induced protection.

Npj viruses·2026
Same author

Advances in Alphavirus and Flavivirus Research II.

Viruses·2026
Same author

A novel chimpanzee-derived adenovirus, a recombinant of Mastadenovirus exoticum and Mastadenovirus blackbeardi members, reveals lineage-specific recombination hotspots in simian adenoviruses.

Virology·2026
Same author

Small extracellular vesicles from DENV2-infected C6/36 cells show viral infection <i>in vitro</i> and <i>in vivo</i>.

Emerging microbes & infections·2026
Same author

Seroprevalence of Neutralizing Antibodies in Healthy Adults, in Mexico, Against Human and Simian Adenovirus Types.

Viruses·2025
Same author

Recent Advances in Vaccine Development for Flaviviruses and Alphaviruses.

Vaccines·2025

Related Experiment Video

Updated: Sep 22, 2025

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease
04:23

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

Published on: April 28, 2019

6.7K

Dengue Vaccines: An Update.

Jesús M Torres-Flores1, Arturo Reyes-Sandoval2, Ma Isabel Salazar3

  • 1Consejo Nacional de Ciencia y Tecnología, 03940, Mexico, DF, Mexico.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|May 24, 2022
PubMed
Summary
This summary is machine-generated.

Developing dengue virus (DENV) vaccines faces challenges, particularly ensuring safety and efficacy in children. This review examines three promising DENV vaccines: Dengvaxia, TV003, and TAK-003.

More Related Videos

Measuring Dengue Virus RNA in the Culture Supernatant of Infected Cells by Real-time Quantitative Polymerase Chain Reaction
08:36

Measuring Dengue Virus RNA in the Culture Supernatant of Infected Cells by Real-time Quantitative Polymerase Chain Reaction

Published on: November 1, 2018

32.1K
Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1
06:18

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1

Published on: March 13, 2018

14.4K

Related Experiment Videos

Last Updated: Sep 22, 2025

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease
04:23

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

Published on: April 28, 2019

6.7K
Measuring Dengue Virus RNA in the Culture Supernatant of Infected Cells by Real-time Quantitative Polymerase Chain Reaction
08:36

Measuring Dengue Virus RNA in the Culture Supernatant of Infected Cells by Real-time Quantitative Polymerase Chain Reaction

Published on: November 1, 2018

32.1K
Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1
06:18

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1

Published on: March 13, 2018

14.4K

Area of Science:

  • Medical Entomology
  • Vaccinology
  • Infectious Diseases

Background:

  • Dengue virus (DENV) is a major global health threat, infecting approximately 390 million people annually.
  • Developing effective DENV vaccines has been challenging due to complex long-term study requirements and safety concerns, such as vaccine-induced severe dengue.
  • Despite challenges, several DENV vaccines have entered clinical trials.

Purpose of the Study:

  • To review the molecular design, efficacy, and immunogenicity of promising DENV vaccines.
  • To discuss the safety challenges encountered during DENV vaccine development.

Main Methods:

  • Review of scientific literature on DENV vaccines.
  • Analysis of clinical trial data for selected DENV vaccines.
  • Discussion of safety profiles and immunogenicity.

Main Results:

  • Three DENV vaccines—Dengvaxia, TV003, and TAK-003—have demonstrated promising results.
  • Detailed insights into the molecular design, efficacy, and immunogenicity of these three vaccines are provided.
  • Key safety challenges, including the risk of vaccine-induced severe dengue, are highlighted.

Conclusions:

  • Dengvaxia, TV003, and TAK-003 represent significant advancements in DENV vaccine development.
  • Ongoing research and careful evaluation are crucial to overcome safety hurdles and establish effective dengue prevention strategies.